Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms SUP-R
- 07 Aug 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2021.
- 07 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2021.
- 01 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov